Publicaciones científicas en Inglés. 2019

Fontenla A, López-Gil M, Tamargo J, Matía-Frances R, Salgado-Aranda R, Rey-Blas JR, Miracle-Blanco A, Mejía-Martínez E, Pastor-Fuentes A, Toquero-Ramos J, Arias MA, Montilla M, Gómez de la Cámara A, Arribas F, en representación de los investigadores BRAKE-AF.
Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project
DOI: 10.1016/j.rec.2019.09.004 Available online 18 October 2019

López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez-Villanueva P, Escobar Cervantes C, Alonso Martín C, Alonso Salinas GL, Arenas M, Arrarte Esteban VI, Ayala de La Peña F, Castro Fernández A, García Pardo H, García-Sanz R, González Porras JR, López de Sá E, Lozano T, Marco Vera P, Martínez Marín V, Mesa Rubio D, Montero Á, Oristrell G, Pérez de Prado A, Velasco Del Castillo S, Virizuela Echaburu JA, Zatarain-Nicolás E, Anguita Sánchez M, Tamargo Menéndez J; Expert reviewers.
Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations.
Rev Esp Cardiol (Engl Ed). 2019 Sep;72(9):749-759. doi: 10.1016/j.rec.2019.03.019. Epub 2019 Aug 9. English, Spanish. PMID: 31405794

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
Eur Heart J. 2019 Sep 21;40(36):3010-3012. doi: 10.1093/eurheartj/ehz650. PubMed PMID: 31541549.

Tamargo J, Rosano G.
Low-quality of some generic medicinal products represents a matter for growing concern.
Eur Heart J Cardiovasc Pharmacother. 2019 Sep 10. pii: pvz037. doi: 10.1093/ehjcvp/pvz037. [Epub ahead of print] PubMed PMID: 31501855.

Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL.
Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother. 2019 Aug 9. pii: pvz033. doi: 10.1093/ehjcvp/pvz033. [Epub ahead of print] PubMed PMID: 31397840.

Savarese G, Reiner MF, Uijl A, D Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS.
Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases.
Eur Heart J Cardiovasc Pharmacother. 2019 Aug 8. pii: pvz036. doi: 10.1093/ehjcvp/pvz036. [Epub ahead of print] PubMed PMID: 31392312.

Tamargo J
Happy 50th anniversary of amiodarone (1969–2019)
2019 Oct 15;293:115-116. doi: 10.1016/j.ijcard.2019.06.080.

Haller PM, Sulzgruber P, Kaufmann C, Geelhoed B, Tamargo J, Wassmann S, Schnabel RB, Westermann D, Huber K, Niessner A, Gremmel T.
Bleeding and ischemic outcomes in patients treated with dual or triple antithrombotic therapy - systematic review and meta-analysis.
Eur Heart J Cardiovasc Pharmacother. 2019 Jun 14. pii: pvz021. doi: 10.1093/ehjcvp/pvz021. [Epub ahead of print]DOI:https://doi.org/10.1016/j.ijcard.2019.06.080

Ruilope LM, Ruiz-Hurtado G, Barderas MG, de la Cruz JJ, Lucia A, de la Sierra A, Gorostidi M, Vinyoles E, Segura J, Solís J, Arribas F, García-Puig J, Tamargo J, O'Brien E, Volpe M, Whelton PK, Williams B, Banegas JR.
Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals.
Hypertension. 2019 Jul;74(1):130-136. doi: 10.1161/HYPERTENSIONAHA.119.12921. Epub 2019 May 28.

Tamargo J.
Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments.
Eur Cardiol. 2019 Apr;14(1):23-32. doi: 10.15420/ecr.2018.34.2. Review.

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-180. doi: 10.1093/ehjcvp

Tamargo J, Caballero R, Delpón E.
Pharmacotherapy for hypertension in pregnant patients: special considerations
Expert Opin Pharmacother. 2019 Jun;20(8):963-982. doi: 10.1080/14656566.2019.1594773. PMID: 30943045

Nieto-Marín P, Jiménez-Jáimez J, Tinaquero D, ALfayate S, Utrilla RG, Rodríguez Vázquez del Rey MM, Perín F, Sarquella-Brugada G, Montserrat L, Brugada J, Tercedor L, Tamargo J, Delpón E, Caballero R.
Digenic Heterozigosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family
Rev Esp Cardiol (Engl Ed). 2019 Apr;72(4):324-332. doi: 10.1016/j.rec.2018.03.012.

Sanchez M, Romero M, Gómez-Guzman M, Tamargo J, Pérez-Vizcaino F, Duarte J.
Cardiovascular effects of flavonoids
Curr Med Chem. 2018 Dec 19. doi: 10.2174/0929867326666181220094721. PMID: 30569843 [Epub ahead of print]

Tamargo J, Caballero R, Delpón E.
New drugs in preclinical and early stage clinical development in the treatment of heart failure
Expert Opin Investig Drugs. 2019;28(1):51-71. doi: 10.1080/13543784.2019.1551357. PMID:30523722